Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 4:16 AM ET

Biotechnology

Company Overview of Syndax Pharmaceuticals, Inc.

Company Overview

Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company’s lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, In...

400 Totten Pond Road

Suite 110

Waltham, MA 02451

United States

Founded in 2005

13 Employees

Phone:

781-419-1400

Fax:

781-419-1420

Key Executives for Syndax Pharmaceuticals, Inc.

Chief Executive Officer and Director
President and Chief Operating Officer
Age: 44
Co-Founder and Chief Technology Officer
Age: 46
Co-Founder
Age: 58
Co-Founder and Advisor
Compensation as of Fiscal Year 2015.

Syndax Pharmaceuticals, Inc. Key Developments

Syndax Pharmaceuticals, Inc. Enters Clinical Trial Collaboration with Genentech in Cancer Immunotherapy Combining Entinostat and Atezolizumab

Syndax Pharmaceuticals, Inc. announced that it has entered into a clinical collaboration with Genentech to evaluate the safety, tolerability and preliminary efficacy of Syndax's entinostat, an oral small molecule that targets immune regulatory cells (myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)), in combination with Genentech's atezolizumab (MPDL3280A), a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1), in patients with triple-negative breast cancer. Triple-negative breast cancer is estimated to account for 10-20% of all diagnosed breast cancers and is characterized by a lack of expression of estrogen receptor (ER-), progesterone receptor (PR-) and HER2 (HER2-) on the breast cancer cells. Syndax will be responsible for conducting the Phase 1b/2 clinical trial in triple-negative breast cancer and the agreement includes a provision where the parties may extend the collaboration to include a Phase 3 clinical trial as well as additional trials in new indications of mutual interest.

Syndax Pharmaceuticals Announces Management Changes

Syndax Pharmaceuticals has named Briggs Morrison as CEO and a member of the board, and Michael Metzger as president and COO. Morrison joins Syndax from AstraZeneca, where he was chief medical officer. He replaces Arlene Morris in the CEO role, who left in May to pursue other endeavors, said a company spokeswoman. Metzger joins from Regado Biosciences, where he was president and CEO through the company's strategic merger with Tobira Therapeutics.

Briggs Morrison to Join Syndax Pharmaceuticals as Head of Global Late-Stage Drug Development

Outgoing Chief Medical Officer of AstraZeneca Briggs Morrison will join Syndax Pharmaceuticals. Morrison, who joined the pharmaceutical company in 2012, is also serving the company as head of global late-stage drug development.

Similar Private Companies By Industry

Company Name Region
Nanotronics, Inc. United States
Intezyne Technologies, Inc. United States
Prion Developmental Laboratories, Inc. United States
Argyll Biotechnologies, LLC United States
Toma Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 1, 2015
--
Private Placement
January 7, 2015
--
Private Placement
September 18, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Syndax Pharmaceuticals, Inc., please visit www.syndax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.